Immunoprotein Diagnostic Testing Market Size, Share & Trends Analysis Report By Test, By Technology, By Application, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2024 - 2030

Market Size & Trends

The global immunoprotein diagnostic testing market size was valued at USD 8.90 billion in 2023 and is projected to grow at a CAGR of 7.7% from 2024 to 2030. Several key factors are driving the market growth including growing demand for personalized medicine, and technological advancements. High prevalence of chronic disorders, such as infectious diseases, cancer, cardiovascular disease, obesity, diabetes, and rheumatoid arthritis has led to the growth of immunoprotein diagnostic testing products.

According to the World Health Organization (WHO), 35 million new cancer cases are predicted in 2050. Due to this, fast and accurate diagnosis of such chronic diseases is important to reduce high mortality and immunoprotein diagnostic testing devices & reagents have proved to be highly effective in the early detection of chronic diseases.

Research and development in technology have introduced new devices and technology in the immunoprotein diagnostic testing market. Increased investment by private players and government initiatives are driving the market growth.

Test Insights

The immunoglobulin diagnostic tests segment dominated the market and accounted for a share of 26.0% in 2023. Immunoglobin is Y shaped molecule which are produced by plasma cells. It has mainly three functions such as neutralizing foreign invaders, coating foreign invaders and stimulating the immune system. The efficiency of immunoglobulin diagnostic test to help healthcare professionals to gather information about immune system of the patient.

The C-Reactive Protein (CRP) diagnostic tests segment is expected to grow at a CAGR of 8.1% over the forecast period. This is owing to an increase in the use of CRP diagnostic test by healthcare professionals to find inflammation caused by various conditions such as infections and autoimmune disorders. CRP is a protein produced by the liver and when there is inflammation due to infection, disease or injury CRP levels increases.

Application Insights

The infectious disease testing segment held the largest share of 25.1 % in 2023 owing to the rise of infectious diseases such as HIV1, HIV2, Hepatitis B, Hepatitis C and Malaria. Rapid diagnosis of infectious diseases, shift from centralized testing in laboratories to decentralized testing in different point of care testing, and technological advancements have improved accuracy, speed and accessibility in this segment.

The oncology testing segment in the global immunoprotein diagnostic testing market is expected to grow at a significant CAGR of 8.5% over the forecast period. According to WHO, about 1 in 5 people develop cancer in their lifetime.  This is expected to be the propelling factor for testing by healthcare professionals. Many countries are investing in facilities to curb increasing cancer cases which is anticipated to lead to the market growth of oncology testing.

Technology Insights

The enzyme based immunoassay segment dominated the global immunoprotein diagnostic testing market in 2023 and it is expected to be retain its dominance during the forecast period. This is due to role of enzyme based immunoassay in diagnosing infectious diseases. Laboratories and healthcare services are undertaking automated diagnostic testing. Improvement in enzyme immunoassay technologies have improved test sensitivity, specificity and speed.

The chemiluminescence assay segment is expected to grow at CAGR of 8.7%. Chemiluminescence assay tests are widely used in the detection of chronic diseases, such as autoimmune disease, infectious disease, cardiovascular disease, obesity, diabetes and cancer. Chemiluminescence assay is also used by various pharmaceutical companies and research institutes for therapeutic drug monitoring. The increasing awareness about the early diagnosis of chronic diseases and the increasing drug research and development activities by pharmaceutical companies are considered to have a high impact on the market growth.

End Use Insights

The hospitals and clinics dominated the market with a share of 45.5% in 2023. Hospitals and clinics cater to many patients on a daily basis, leading to a high demand for diagnostic testing services. Hospitals often have specialized departments and advanced medical equipment that enable them to provide accurate and timely immunoprotein diagnostic testing services. The shift from centralized testing to decentralized testing has propelled the growth of the market. Technological advancement in the healthcare sector also has propelled the market growth.

The diagnostic laboratories segment is expected to grow at a CAGR of 8. 7% during the forecast period. Diagnostic laboratories are expected to grow due to increased accessibility and speed and convenience for patients. Awareness about the importance of early diagnosis in chronic condition is driving the market growth.

Distribution Channel Insights

The retail sales segment dominated the market with a revenue share of 54.5% in 2023. This can be attributed to accessibility and convenience for the patients. Retail sales make immunoprotein diagnostic tests readily available to individuals. Also, retail sales offer convenient access to immunoprotein diagnostic tests enabling patients to take control of their health. They play a crucial role in raising awareness about the importance of diagnostic testing among the general population, driving market growth.

The direct tender segment is expected to grow at a CAGR of 7.8% during the forecast period. Direct tender offers a streamlined process of procurement for healthcare facilities and institutions where the demand for these tests is in big volume. This direct tender arrangement often results in cost savings for buyers due to bulk purchasing and negotiated pricing which makes it an attractive option for healthcare providers. Also, direct tender arrangements allow for the customization of products and services based on the specific needs of healthcare providers.

Regional Insights

North America dominated the market with a revenue share of 42.8% in 2023. It is attributable to technological advancements, high prevalence of chronic diseases and increasing research and development investments. The region has well established healthcare infrastructure with advanced medical facilities, skilled healthcare professionals, and robust regulatory frameworks. This facilitates easy access to immunoprotein diagnostic testing services for patients, contributing to the market dominance.

U.S. Immunoprotein Diagnostic Testing Market Trends

The U.S immunoprotein diagnostic testing market dominated the North America market with a share of 78.1% in 2023. The increasing prevalence of chronic diseases, such as cancer, cardiovascular diseases, and autoimmune disorders, in the U.S. drives the demand for immunoprotein diagnostic testing to aid in early detection and monitoring of these conditions. Also, the U.S. has stringent regulatory standards enforced by agencies like the United States Food and Drug Administration, ensuring the quality and safety of diagnostic tests, which enhances consumer trust and confidence in the market.

Europe Immunoprotein Diagnostic Testing Market Trends

The Europe immunoprotein diagnostic testing market is expected to witness significant growth driven by factors such as the increasing prevalence of chronic diseases in the region, technological advancements, growing geriatric population, focus on personalized medicine, government initiatives and rising healthcare expenditure. These key drivers are shaping the landscape of immunoprotein diagnostic testing in Europe, leading to improved patient care and outcomes.

The UK immunoprotein diagnostic testing market is expected to grow significantly in the coming years due to increasing awareness and improved diagnosis methods. Government organizations such as National Health Services UK are taking initiatives such as NHS long term plan with goals to protect people from cancer.

The Germany immunoprotein diagnostic testing market held a substantial market share in 2023 owing to the increasing geriatric population and need for personalized medicine and treatment. Immunoprotein tests help healthcare providers to determine individualized treatment plans based on a patient’s specific protein markers, driving the market growth.

Asia Pacific Immunoprotein Diagnostic Testing Market Trends

Asia Pacific immunoprotein diagnostic testing market is anticipated to witness the fastest CAGR of 9.9% in the coming years. This growth is due to increasing investment in the healthcare industry by government and private companies. The increasing geriatric population in the region and government initiatives to spread awareness and control diseases such as cancer, HIV and other infectious diseases are propelling the market growth in the region.

The Japan immunoprotein diagnostic testing market is expected to witness significant growth during the forecast period, 2024 to 2030 owing to the improved diagnosis methods and technological advancements.

India is to expect to witness growth in immunoprotein diagnostic testing market over the forecast period due to increasing prevalence of Cancer and HIV diseases. According to the National Aids Control Organization there are more than 24 lakh people living with HIV in 2022.

Immunoprotein Diagnostic Testing Company Share & Insights

Some of the key companies in the immunoprotein diagnostic testing market include Agilent Technologies, Inc.; Danaher Corporation; Thermo Fisher Scientific Inc.; PerkinElmer Inc. Organizations in the market are focusing on increasing customer base to gain a competitive edge in the industry. Key players are taking several strategic initiatives, such as mergers and acquisitions, and partnerships with other major companies. 

Recent Developments

• In July 2023, Quest Diagnostics, one of the major players in the diagnostic testing market, launched its first diagnostic test in the open market related to Alzheimer's disease. The AD-Detect Test for Alzheimer's Disease test made available through an online platform offers an examination of brain protein and shares an assessment measuring potential risks associated with the disease.

• In July 2023, Siemens Healthineers, a German organization operating in the healthcare technology and automation industry, launched one of its latest innovations, Atellica CI Analyzer. The new addition to Siemens’ diverse portfolio, dealing with immunoassay and clinical chemistry testing has attained clearance from the FDA and is distributed among multiple regional markets now.

Immunoprotein Diagnostic Testing Market Report Scope

Global Immunoprotein Diagnostic Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global immunoprotein diagnostic testing market report based on test, technology, material, fluid, application and region.

• Test Outlook (Revenue, USD Million, 2018 - 2030)

  • Complement System Proteins Diagnostic Tests

  • Free Light Chain Diagnostic Tests

  • Haptoglobin Diagnostic Tests

  • Immunoglobulin Diagnostic Tests

  • Prealbumin Diagnostic Tests

  • C-Reactive Protein (CRP) Diagnostic Tests

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Infectious Disease Testing 

  • Oncology Testing

  • Endocrine Testing

  • Toxicology Testing

  • Allergy Testing

  • Autoimmune Disease Testing

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • Radioimmunoassay

  • Enzyme Based Immunoassay

  • Chemiluminescence Assay

  • Immunofluorescence Assay

  • Immunoturbidity Assay

  • Immunoprotein Electrophoresis

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals and Clinics

  • Diagnostic Laboratories

  • Others

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Direct Tender

  • Retail Sales

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait